2025 Multiple Myeloma – Integrating innovation from bench to clinic
Dates: 3/4 novembre 2025
Location: Genova, Italy
Over the recent years significant progress has been achieved in Multiple Myeloma biology resulting in novel therapeutic strategies as well as changes in the whole treatment paradigm. This international meeting aims to update the state of the art in Multiple Myeloma focusing on the latest biological and clinical advances. A number of internationally recognized speakers are expected to deliver updates lectures on cutting edge topics. These will include genetic and epigenetic features of biology, molecular and biological mechanisms of disease progression, new prognostic factors and novel approaches to evaluate the response to therapy, new therapeutic molecules and combinations targeting tumor cells and/or their microenvironment. Novel immunotherapy strategies will also be the object of intensive scrutiny.
We are confident that at the end of the meeting all of us will be enriched with fresh stimuli and renewed enthusiasm, with the deep awareness that the enduring challenges posed by Multiple Myeloma may now be faced with more rational and effective achievements.
Prof. Roberto Massimo Lemoli, Meeting President
Additional information
Date
- Monday, November 3, 2025
- Tuesday, November 4, 2025
Location
NH Marina Collection Hotel
Molo Ponte Calvi, 5, 16124 Genova GE
MEETING PRESIDENT
- Prof. Roberto M. Lemoli
SCIENTIFIC COMMITTEE
- Michele Cea (Chair)
- Antonia Cagnetta
- Matteo Garibotto
- Marco Olivieri
- Maria Elisabetta Catini
- Marco Gallo
- Anna Elisa Laserra
FACULTY To be confirmed
- ANGELUCCI Emanuele IRCCS Polyclinic San Martino – Hematology and Cellular Therapies Operational Unit-Genoa, Italy
- BELLONE Matteo Maria IRCCS San Raffaele Hospital – Clinical Unit of Immunology, Rheumatology, Allergology and Rare Diseases – Milan, Italy
- BOLLI Niccolò University of Milan – Hematology – Milan, Italy
- BRUNO Benedetto University of Turin, AOU Città della Salute e della Scienza – University Division of Hematology – Turin, Italy
- CAGNETTA Antonia University of Genoa, IRCCS Polyclinic San Martino – UOC Hematology Clinic – Genoa, Italy
- CAVO Michele University of Bologna – University Division of Hematology – Bologna, Italy
- CEA Michele University of Genoa, IRCCS Polyclinic San Martino – UOC Hematology Clinic – Genoa, Italy
- D’AGOSTINO Mattia University of Turin, AOU Città della Salute e della Scienza – Molecular Biotechnology and Health Science – Hematology – Turin, Italy
- DA VIA’ Matteo Claudio IRCCS Ca’ Granda Maggiore Hospital Polyclinic – Hematology – Milan, Italy
- EINSELE Hermann Julius Maximilians University Würzburg – Internal Medicine II – Würzburg, Germany
- GIULIANI Nicola University of Parma – Hematology – Parma, Italy
- GOBBI Marco University of Genoa – Emeritus professor – Genoa, Italy
- GULLA’ Annamaria Candiolo Cancer Institute – IRCCS – Laboratory of Translational Hematology and Immunology – Candiolo TO, Italy
- KORST Charlotte Amsterdam University – Department of Hematology – Amsterdam, The Netherlands
- LEMOLI Roberto Massimo University of Genoa, IRCCS Polyclinic San Martino – UO Hematology Clinic – Genoa, Italy
- MALAVASI Fabio University of Turin – Emeritus professor – Turin, Italy
- MATEOS MANTECA María Victoria University of Salamanca – Biomedical Research Institute – Hematology Service – Salamanca, Spain
- MORELLI Eugenio Candiolo Cancer Institute – IRCCS – Laboratory of Translational Research – Candiolo TO, Italy
- RASCHE Leo University of Würzburg – Department of Internal Medicine – Würzburg, Germany
- ROCCARO Aldo Maria University of Brescia, ASST Spedali Civili Hospital – Clinical Trial Center and Phase I Studies, Research and Innovation – Brescia, Italy
- RUGGERI Piero University of Genoa – Dean School of Medical and Pharmaceutical Sciences – Genoa, Italy
- TACCHETTI Paola University of Bologna, IRCCS AOU of Bologna – Institute of Hematology “Seràgnoli” – Bologna, Italy
- TERRAGNA Carolina IRCCS AOU of Bologna – Polyclinic Sant’ Orsola – Laboratory of Molecular Biology – Bologna, Italy
- UCCELLI Antonio IRCCS Polyclinic San Martino – Scientific Director – Genoa, Italy
- ZAMAGNI Elena University of Bologna, Polyclinic Sant’ Orsola Institute of Hematology “Seràgnoli”-Bologna, Italy
Preliminary Programme
Monday, November 3, 2025
08:30 Registration
OPENING SESSION
09:00 Welcome address – R.M. Lemoli, P. Ruggeri, A. Uccelli
09:30 Lecture Cellular Therapies for Multiple Myeloma: Engineering Hope – H. Einsele
Introducing – R. M. Lemoli
BIOLOGY OF MULTIPLE MYELOMA: GENOMIC, EPIGENOMIC AND PROTEOMIC INSIGHTS
Chairpersons: N. Bolli, A. Roccaro
10:15 The supportive role of the endothelial niche in myeloma biology – A. Roccaro
10:40 CD38, NAD+ Metabolism and Resistance Mechanisms – F. Malavasi
11:05 Genomic complexity during disease progression from smouldering to multiple myeloma – M.C. Da Vià
11:30 Unique molecular assay (UMA): a next generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma – C. Terragna
11:55 Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes – N. Bolli
12:20 From targeted to cellular therapy: an unexpected role for RNA? – E. Morelli
12:55 Lunch
IMMUNOMETABOLISM, MICROENVIROMENT AND IMMUNOTHERAPIES
Chairpersons: M. Cea, N. Giuliani
14:00 Unraveling the biological underpinning of tumor immune escape – A. Gullà
14:25 New insights on myeloma bone disease pathogenesis – N. Giuliani
14:50 The nutrition-microbiota immunity axis in multiple myeloma – M.M. Bellone
15:15 Targeting metabolic pathways – M. Cea
15:40 Coffee Break
PRECISION MEDICINE APPROACH AND REAL-WORLD DATA
Chairpersons: B. Bruno, M. Gobbi
16:00 Current approaches for high-risk smouldering myeloma – M.V. Mateos Manteca
16:25 Tailoring Treatment for Elderly and Frail Patients – S. Bringhen
16:50 MRD-guided therapeutic strategies – M. D’Agostino
17:15 Management of Monoclonal Gammopathy of Clinical Significance – A. Cagnetta
17:40 Closing – R.M. Lemoli, M. Cea
Tuesday, November 4, 2025
MANAGEMENT OF HIGH-RISK PATIENTS AND RELAPSE
Chairpersons: F. Gay, E. Zamagni
09:00 How I treat high risk patients – E. Zamagni
09:25 Novel strategies for induction therapy in transplant-elegible patients – F. Gay
09:50 Novel strategies for relapsing patients – P. Tacchetti
10:15 Coffee Break
PUSHING FORWARD EXPERIMENTAL, PRECLINICAL AND CLINICAL RESEARCH
Chairpersons: E. Angelucci, R.M Lemoli
10:30 Preclinical Modeling of Myeloma: From Xenografts to Transgenics – tbd –
10:55 Single cell analysis discloses the spatial architecture of myeloma and its microenviroment – L. Rasche
11:20 Bispecific Monoclonal Antibodies: Harnessing immunity to treat multiple myeloma – M. Cavo
11:45 Shaping the future of immunotherapy for multiple myeloma: trispecific monoclonal antibodies – C. Korst
12:10 Keynote Lecture Future Directions in Myeloma Research: Integration and Innovation – B. Bruno
Introducing – M. Cea
CLOSING SESSION
12:40 Closing remarks – R.M. Lemoli, M. Cea
12:50 CME Test
13:00 Closing of the Meeting
ECM / CME (only for italian participants)
ECM will be available for:
- Medical doctors
- Biologists
– In process of accreditation –
Participation is free but online registration is required.
No onsite registrations will be accepted.
Registration deadline: Friday 24 October, 2025 at 11.00 AM
For online registration click below:
ORGANIZING SECRETARIAT
eventually
sedi: mondovì (cn) / torino (italy)
email: info@eventuallyevents.it
phone & whatsapp: +39.327.3752740
PROVIDER E.C.M. N° 1038 Staff P&P
FOLLOW US
If you want to book a room at the conference venue:
NH Collection Marina
For reservation: Click here
Sponsor&partner
Sponsors & partners
Patronage of
Non-conditional contribution of